Brighton, United Kingdom – 9th May, 2017 – Destiny Pharma, a clinical stage biotech company focused on the development of new anti-microbial drugs, is pleased to announce that one of its Board members, Professor David Roblin, has been elected to the Academy of Medical Sciences. David has been a director of Destiny Pharma since 2011 and the Board of Destiny congratulates him on this prestigious award.
David has recently been appointed Chief Operating Officer and President of R&D of Summit Therapeutics. Prior to this, he was Chief Operating Officer and Director of Scientific Translation at the Sir Francis Crick Institute. He was also formerly Senior Vice President and Head of R&D for Pfizer’s European sites, as well as Head of Therapy Area for Anti-Infectives at Bayer. David has a first degree in biochemistry from University College London and later qualified in medicine from St George’s Hospital.
Previous recipients include Professor Françoise Barré-Sinoussi, director of Unité de Régulation des Infections Rétrovirales, Chen Zhu, China’s Minister of Health, and Sir Andrew Witty, the former Chief Executive Officer of GlaxoSmithKline.
For full details of the announcement please visit: https://www.crick.ac.uk/news/news-archive/2017/05/08/david-roblin-and-robert-wilkinson-elected-to-the-academy-of-medical-sciences/
For further information, please visit www.destinypharma.com or contact:
Destiny Pharma Ltd
Simon Conway / Victoria Foster Mitchell / Hanna Skeppner
+44 (0) 2037 271000
Notes for Editors
About the Academy of Medical Sciences
The Academy of Medical Sciences is the independent body in the UK representing the diversity of medical science. Our elected Fellows are the UK’s leading medical scientists from hospitals, academia, industry and the public service. Our mission is to advance biomedical and health research and its translation into benefits for society. We are working to secure a future in which:
- UK and global health is improved by the best research.
- The UK leads the world in biomedical and health research, and is renowned for the quality of its research outputs, talent and collaborations.
- Independent, high quality medical science advice informs the decisions that affect society.
- More people have a say in the future of health and research.
Our work focusses on four key objectives, promoting excellence, developing talented researchers, influencing research and policy and engaging patients, the public and professionals.
About Destiny Pharma Ltd
Destiny Pharma is a clinical stage biotechnology company focused on the development of novel anti-infective drugs to combat antibiotic-resistant bacteria, addressing a growing global unmet clinical need. Destiny’s patented XF drug platform represents a new approach to treat infectious disease, based on a novel molecular structure and a unique mechanism of action. XF drugs, unlike conventional antibiotics, are able to kill bacteria in any growth phase ultra-rapidly, with lower potential for the emergence of drug resistance.
The Company has completed five successful Phase I/IIa clinical trials with its lead drug, XF-73 (exeporfinium chloride). XF-73 has been awarded Qualifying Infectious Disease Product (QIDP) status and is being initially developed for the prevention of post-surgical staphylococcal infections, a potentially blockbuster indication of high unmet medical need. Destiny’s XF drug platform is being developed to prevent and treat existing and emerging “superbug” infections with a broad range of application in both primary and secondary healthcare settings.